#ClinicalTrial EAQ221CD/CONCURxP monitors CDK4/6 inhibitor medication use with text message reminders & alerts for patients treated for #BreastCancer . For more information: bit.ly/EAQ221CD #bcsm cc: Gelareh Sadigh, MD, Ilana G

.Amer Zeidan MBBS,MHS ‏عامر زيدان of Smilow Cancer Hospital & Yale Cancer Center is leading clinical study EA9171, testing if adding a new drug to the usual treatment for chronic myelogenous #leukemia could help patients. Learn more: bit.ly/ea9171-study #CML #leusm

Watch “Cancer Luminaries Episode 2: Dr. Otis Brawley Talks about Cancer Disparities as Barriers to Better Outcomes for All” The University of Chicago Otis Brawley vimeo.com/939593672 #equity #HealthyLiving #healthylifestyle #Cancer

Have you listened to Cancer Luminaries, our podcast series discussing the past, present and future of cancer research? Our first two episodes feature Todd Golub and Otis Brawley. ow.ly/xw9f50RpgtL #UChiCancer50 Johns Hopkins Kimmel Cancer Center Broad Institute

The EAF223/GABLE clinical study is testing different imaging techniques that could help make better predictions about #BrainCancer progression. Learn more here: bit.ly/gable-trial
cc: Duke Radiology, Glioblastoma Foundation, GBM Foundation

In #ClinicalTrial EA2222/PUMP, investigators are testing #PumpChemo in addition to SOC chemo versus SOC chemo alone for patients with unresectable #ColorectalCancer liver metastases. For more: bit.ly/ea2222-pump cc : Michael Lidsky, MD, FACS

Urothelial cancer is the most common type of #bladdercancer . The EA8192 study is evaluating durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. bit.ly/ea8192-trial cc: Bladder Cancer Advocacy Network Jean Hoffman-Censits Petros Grivas

Do you have #KidneyCancer ( #RenalCellCarcinoma ) that has spread to 2-5 other locations in your body?
If so, you may be able to participate in this study of a potential new treatment. Learn more: bit.ly/ea8211-study #kcsm

So proud of Bridget O'Brien, DNP, FNP-BC, AOCNP for bringing together this great group for the inaugural APP Committee in ECOG-ACRIN Cancer Research Group last week! Happy #NursesWeek !

#ClinicalTrial EAQ211/The AYA Social Genomics Study, led by Brad Zebrack of U-M Rogel Cancer Center & University of Michigan School of Social Work, aims to improve care for #AYAs diagnosed with and treated for #lymphoma . Learn more: bit.ly/eaq211-study #AYACancer #AYACSM

#ClinicalTrial EAQ222CD/CostCOM, led by Gelareh Sadigh, MD, is testing the effectiveness of cost communication and financial navigation in patients with #cancer . If you have any newly diagnosed #SolidCancer , you may be able to participate. bit.ly/EAQ222CD

Do you have #ProstateCancer that has returned after prostatectomy? If so, you may be able to participate in this study of potential new treatment approaches. Learn more about the EA8191/INDICATE study: bit.ly/ea8191indicate #pcsm #ProstateCancer Aware cc: @nehavapiwala

Could chemotherapy given both before and after surgery improve outcomes for patients with #GallbladderCancer (compared to chemo given only after surgery)? #ClinicalTrial EA2197/OPT-IN aims to find out. More info: bit.ly/EA2197 cc: Shishir K. Maithel Winship Cancer Institute of Emory University

Phase 2 of #ClinicalTrial EA9152 is now enrolling! This study is exploring a new treatment approach for patients with T-cell or B-cell #ALL that has come back or does not respond to treatment. Learn more here: bit.ly/EA9152 #leukemia #leusm

Over the last several days, we've seen several posts honoring the late Dr. Edith Mitchell, past NMA President at the ECOG-ACRIN Cancer Research Group ECOG Spring 2024 meeting. It would be remiss of us to not share our sympathies and condolences. 

LaPrincess C. Brewer, MD, MPH National Medical Association Edith Mitchell, M.D.

🧵/ 1

Soon to open Sylvester Comprehensive Cancer Center - ECOG-ACRIN Cancer Research Group 5221: A trial designed to study the role of chemo vs IO in elderly pts w #lungcancer 👇🏽